Skip to main content

Table 5 ICER depending on management of local relapse, given in € (2015)

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

   bootstrapped CI Fieller CI
ICER (€/LY) lower 95% (€) upper 95% (€) lower 95% (€) upper 95% (€)
mean total costs: re-RT always as IMRT
 no discount 16.83 − 146.34 180.76 −20,478 5788
 3.5% discount 17.43 − 147.08 174.73 −31,332 6617
 3.0% discount 17.38 −144.36 207.18 −29,647 6512
adjusted (Lin1):
 adjusted, no discount 20.98     
 adjusted, 3.5% disc. 20.64     
 adjusted, 3.0% disc. 20.56     
mean total costs: re-RT always as C12
 no discount 14.64 − 122.02 124.56 −15,476 3849
 3.5% discount 12.86 −104.32 139.57 −20,367 3475
 3.0% discount 12,840 −102.66 148.36 −19,130 3410
adjusted (Lin1):
 adjusted, no discount 23.91     
 adjusted, 3.5% disc. 22.24     
 adjusted, 3.0% disc. 22.32